Month: April 2020

Post-hoc analysis from 6 years of Phase III open-label extension studies showed OCREVUS treatment reduced the risk of needing a walking aid (EDSS≥6) by 49% in relapsing multiple sclerosis (RMS) patients compared with patients who switched from interferon beta-1a two years laterSeparate analysis showed OCREVUS slowed thalamic volume loss in patients with RMS and primary progressive MS (PPMS) vs. interferon beta-1a and placebo, respectivelyMore than 150,000 people have been treated with OCREVUS globally, in clinical trial and real-world settings; data continue to show a consistent and favourable benefit-risk profile             Basel, 28 April 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new analyses of Phase III OPERA I and OPERA II studies, as well as the open-label extensions, showing that OCREVUS® (ocrelizumab) treatment...

L’étude translationnelle initiale, EXPLORE, a montré une surexpression de la voie C5a/C5aR chez les patients présentant un COVID-19 sévèreInnate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui que le premier patient a été traité dans un essai clinique randomisé en double aveugle de Phase II évaluant la tolérance et l’efficacité d’avdoralimab (IPH5401), son anticorps anti-C5aR, chez des patients atteints d’un COVID-19 entrainant une pneumonie sévère.L’objectif de cet essai clinique indépendant, nommé FORCEa, est d’améliorer la proportion de patients atteints d’une pneumonie sévère due au COVID-19 qui n’ont plus besoin d’être hospitalisés, et de réduire le besoin et la durée de ventilation mécanique chez les patients atteints d’une pneumonie compliquée par un syndrome...

Initial translational analysis, EXPLORE, showed overexpression of C5a/C5aR pathway in patients with severe COVID-19Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a randomized, double-blind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab (IPH5401), in COVID-19 patients with severe pneumonia.The primary objective of this investigator-sponsored trial, named FORCEa, is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS). The Phase II trial is supported by an exploratory translational...

AB Klaipėdos nafta, legal entity code 110648893, registered address Buriu str. 19, Klaipeda (hereinafter – the Company), by initiative of Board and its Resolution on 10 April 2020 1:00 p. m. was convened an Extraordinary General Meeting of Shareholders of the Company (hereinafter – the General meeting of shareholders), during which it was decided to increase authorized capital of the Company by additional contributions issuing 138 236 units of ordinary registered shares.Newly issued shares issue price determined according to the weighted average market price of shares of the Company within 6 months for the period from 1 October 2019 to 1 March 2020 and it is equal to 0,38 EUR for 0,29 EUR nominal value share.The requirements of Law on Securities (hereinafter – the LS) on prospectus preparation, approval and publication it is not applied...

AB „Klaipėdos nafta“, juridinio asmens kodas 110648893, registruota buveinė adresu Burių g. 19, Klaipėda (toliau – Bendrovė), valdybos iniciatyva ir sprendimu 2020 m. balandžio 10 d. 13:00 val. buvo sušauktas Bendrovės neeilinis visuotinis akcininkų susirinkimas (toliau – Visuotinis akcininkų susirinkimas), kurio metu buvo nuspręsta padidinti Bendrovės įstatinį kapitalą papildomais įnašais išleidžiant iki 138 236 vnt. paprastųjų vardinių akcijų.Naujai išleidžiamų akcijų emisijos kaina nustatoma vadovaujantis vidutine svertine Bendrovės akcijų rinkos kaina per 6 mėnesius už laikotarpį nuo 2019 m. spalio 1 d. iki 2020 m. kovo 1 d. ir yra lygi 0,38 EUR už 0,29 EUR nominalios vertės akciją.Vertybinių popierių įstatymo (toliau – VPĮ) reikalavimai dėl prospekto rengimo, tvirtinimo ir paskelbimo šiai Bendrovės akcijų emisijai yra netaikomi,...

FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants aged 1-7 months after 12 months of treatmentLarge, pivotal global study confirms clinically meaningful efficacy seen in the dose-finding Part 1 of the trialSafety was consistent with the safety profile observed to date and no new safety signals were identifiedBasel, 28 April 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1 – 7 months old with symptomatic Type 1 spinal muscular atrophy (SMA). The study met its primary endpoint with 29% of infants (12/41; p

MARSEILLE, France, April 28, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a randomized, double-blind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab (IPH5401), in COVID-19 patients with severe pneumonia.The primary objective of this investigator-sponsored trial, named FORCEa, is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS). The Phase II trial is supported by an exploratory translational study, EXPLORE COVID-19, which suggests that...

eQ PLC INTERIM REPORT28 April 2020 at 8:00 AMJanuary to March 2020 in brief During the period under review, the Group’s net revenue totalled EUR 12.0 million (EUR 11.6 million from 1 Jan. to 31 March 2019). The Group’s net fee and commission income was EUR 11.7 million (EUR 11.3 million).The Group’s net investment income from own investment operations was EUR 0.3 million (EUR 0.3 million), including the return from private equity fund investments and liquid fixed income funds.The Group’s operating profit grew by 13% to EUR 6.0 million (EUR 5.3 million).The Group’s profit was EUR 4.8 million (EUR 4.2 million).The consolidated earnings per share were EUR 0.13 (EUR 0.11).The net cash flow from the Group’s own private equity fund investment operations was EUR 0.5 million (EUR -0.3 million).The net revenue of the Asset Management segment...

eQ OYJ OSAVUOSIKATSAUS28.4.2020, klo 8:00Tammi-maaliskuu 2020 lyhyestiKonsernin nettoliikevaihto oli katsauskaudella 12,0 miljoonaa euroa (11,6 M€ 1.1.-31.3.2019).Konsernin nettopalkkiotuotot olivat 11,7 miljoonaa euroa (11,3 M€).Konsernin oman sijoitustoiminnan nettotuotot olivat 0,3 miljoonaa euroa (0,3 M€) sisältäen tuotot pääomarahastosijoituksista ja likvideistä korkorahastoista.Konsernin liikevoitto kasvoi 13 prosenttia ja oli 6,0 miljoonaa euroa (5,3 M€).Konsernin tulos oli 4,8 miljoonaa euroa (4,2 M€).Konsernin osakekohtainen tulos oli 0,13 euroa (0,11 euroa).Konsernin oman pääomarahastosijoitustoiminnan nettokassavirta oli 0,5 miljoonaa euroa (-0,3 M€).Varainhoito-segmentin nettoliikevaihto kasvoi 10 prosenttia 11,3 miljoonaan euroon (10,3 M€) sekä liikevoitto 21 prosenttia 6,4 miljoonaan euroon (5,3 M€).Corporate Finance -segmentin...